Palvella Therapeutics announces results from Phase 2 study of QTORIN
Palvella Therapeutics (PVLA) announced results from the Phase 2 study of QTORIN 3.9% rapamycin anhydrous gel for the treatment of microcystic ...
来自MSN3 天
Palvella Therapeutics Reports Promising Results for QTORIN Rapamycin in Treating Rare ...
Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced positive outcomes from a Phase 2 study evaluating QTORIN™ 3.9% ...
来自MSN1 个月
Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease ...
A key focus is the continued development of QTORIN™ rapamycin, a patented anhydrous gel designed to treat microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations ...
Business Insider1 个月
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and ...
Kaupinen. “This transaction will enable us to accelerate late-stage development of QTORIN™ rapamycin, our lead product candidate, for microcystic LMs and cutaneous VMs while also further ...